Business Wire Industry News

Wednesday, January 27, 2021

Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion cohort portion of the ongoing Phase 1 clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate (ADC). Supporting data from the Phase 1 dose escalation portion were highlighted today via a webcast and conference call and are summarized below

Wednesday, January 27, 2021

Cybin Included in First Psychedelic Exchange Traded Fund

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it is among the select companies in the U.S. and Canada to be included in the world’s first exchange-traded fund (“ETF”) for psychedelic drug companies. The Horizons Psychedelic Stock Index ETF is trading on the NEO Exchange under the ticker symbol PSYK and will track the North American Psychedelics Index. “Investor interest in

Wednesday, January 27, 2021

ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury

EINDHOVEN, Netherlands & LAUSANNE, Switzerland--(BUSINESS WIRE)--ONWARD today announced the publication of a study in the journal, Nature, which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI). “A serious and underrecognized result of spinal cord injury is unstable blood pressure, which can have devastating consequences that reduce quality of life and are life threatening. Unfortunately, there are no effective therapies for uns

Tuesday, January 26, 2021

FSD Provides Corporate Update

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces the following corporate updates. Corporate Update The Company continues to pursue its strategy of completing a Phase 2 clinical trial for the use of its lead compound, ultramicronized-palmitoylethanolamide (or ultramicronized PEA) (“FSD201”), to treat hospitalized COVID-19 patients in a double-blind study (the “Study”). The Company is expected to randomize 352 patients with COVID

Tuesday, January 26, 2021

Titan Medical Announces Closing of US $11.5M Bought Deal Offering Including Full Exercise of Over-Allotment Option

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 6,451,613 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of approximately US $10,000,000.00 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwri

Tuesday, January 26, 2021

SoundBite Medical Solutions Announces First Use of its Novel 0.014” Active Wire to Successfully Treat Calcified Below-The-Knee CTOs

MONTREAL--(BUSINESS WIRE)--SoundBite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO). The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of Internal Medicine, and PD Dr Rief at the Medical University of Graz, Austria. “Va

Tuesday, January 26, 2021

AI Genomics Company, NRGene, Completes Initial Public Offering on Tel-Aviv Stock Exchange and Raises NIS 100 Million (~US$30 Million)

NESS ZIONA, Israel & SAN DIEGO & SASKATOON, Saskatchewan--(BUSINESS WIRE)-- #AI--NRGene (Tel Aviv Stock Exchange: NRGN), an AI based genomic company operating in the agricultural and livestock industry, announced today that it has successfully completed its initial public offering on the Tel Aviv Stock Exchange (TASE). NRGene raised ~NIS 100 Million (~US$30 Million), with a post-money valuation of circa NIS 370 Million (~NIS 420 Million on a fully diluted basis). Leading institutional entities in the

Monday, January 25, 2021

Kardium Announces $115M in New Financing for Innovative Atrial Fibrillation Treatment

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. The round is led by Fidelity Management & Research Company LLC., together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. The new financing will be used to accelerate commercial growth of the Globe System across Europe and to conduct a clinica

Friday, January 22, 2021

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the

Friday, January 22, 2021

FSD Pharma Sets Date for Annual Meeting

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. The Meeting will address normal course matters, including the presentation of the Company’s audited financial statements, as well as matters contained in a requisition for a special meeting submitted to the Company by certain shareholders of the Company claiming to hold in excess of 5.1% of the C

Friday, January 22, 2021

Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“ Devonian” or the “ Corporation”) ( TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018: 252,055 units at a unit price of $0.20 (the “

Thursday, January 21, 2021

Titan Medical Announces Filing of Final Short Form Prospectus

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed and been receipted for a final short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 6,451,613 units of the Company (“Units”) on a “bought d

Thursday, January 21, 2021

Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units

DENVER--(BUSINESS WIRE)--Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that, in connection with its bought deal offering (the “Offering”) previously announced on January 14, 2021, it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) with

Thursday, January 21, 2021

Mydecine Announces Change of Auditor

DENVER--(BUSINESS WIRE)--Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), announces that the board of directors of the Company has appointed SHIM & Associates LLP, Chartered Professional Accountants as the Company’s new auditor, replacing MNP LLP (“MNP”), Chartered Professional Accountant. The reason for the change in the auditor relates to requirement for the Company’s auditor to review the Company’s interim financial statements in connection w

Thursday, January 21, 2021

Bluma Wellness Inc. Provides End-of-Month Operations Update and Financial Highlights for December 2020

TORONTO--(BUSINESS WIRE)--Bluma Wellness Inc. (the “Company” or “Bluma Wellness”) (CSE: BWEL.U) is pleased to provide its patients and investors with an end-of-month sales and operations report for the month ended December 31, 2020. The financial highlights disclosed in this press release are management prepared and have not been audited or reviewed by the Company’s auditors. Unless otherwise indicated, all amounts are expressed in U.S. dollars. Financial Highlights, December 2020 Bluma Wellnes

Thursday, January 21, 2021

VBI Vaccines Announces Progress of Coronavirus Vaccine Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided an update on the progress of its coronavirus vaccine program, consisting of two vaccine candidates: (1) VBI-2901, a trivalent pan-coronavirus vaccine candidate expressing the SARS-CoV-2 (COVID-19), SARS-CoV (SARS), and MERS-CoV (MERS) spike proteins; and (2) VBI-2902, a monovalent vaccin